Back to top

biotechnology: Archive

Zacks Equity Research

Gilead (GILD) Outpaces Industry in Six Months: What Lies Ahead?

Gilead (GILD) gains on the back of its strong HIV franchise and promising oncology business, which should propel growth further.

GSKPositive Net Change DVAXPositive Net Change GILDPositive Net Change BOLTPositive Net Change

Zacks Equity Research

Bristol Myers (BMY) Announces Milvexian Phase II Study Results

Bristol Myers (BMY) announces AXIOMATIC-SSP study results of milvexian, an investigational oral factor XIa inhibitor, for preventing new symptomatic ischemic stroke or new covert brain infarction.

BMYPositive Net Change DVAXPositive Net Change JNJNegative Net Change BOLTPositive Net Change

Zacks Equity Research

Incyte (INCY) Gets FDA Nod for Label Expansion of Pemazyre

Incyte (INCY) obtains FDA approval for Pemazyre for a second indication - the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.

NVSPositive Net Change DVAXPositive Net Change INCYPositive Net Change BOLTPositive Net Change

Mark Vickery

Top Analyst Reports for Apple, Alibaba & Bristol-Myers Squibb

Today's Research Daily features new research reports on 12 major stocks, including Apple Inc. (AAPL), Alibaba Group Holding Limited (BABA) and Bristol-Myers Squibb Company (BMY).

AAPLNegative Net Change BMYPositive Net Change UNPNegative Net Change CIPositive Net Change TSLAPositive Net Change BABAPositive Net Change

Zacks Equity Research

Bristol Myers (BMY) Up 14.6% YTD: Will the Performance Continue?

Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue on label expansion of existing drugs.

BMYPositive Net Change DVAXPositive Net Change MRKPositive Net Change BOLTPositive Net Change

Zacks Equity Research

Biotech Stock Roundup: GILD, BLUE, AXSM's Drug Approvals, FHTX Study Update & More

Regulatory updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.

GILDPositive Net Change NVAXPositive Net Change AXSMPositive Net Change FHTXPositive Net Change